BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 19267483)

  • 1. SVM model for virtual screening of Lck inhibitors.
    Liew CY; Ma XH; Liu X; Yap CW
    J Chem Inf Model; 2009 Apr; 49(4):877-85. PubMed ID: 19267483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
    Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD
    J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtual screening of Abl inhibitors from large compound libraries by support vector machines.
    Liu XH; Ma XH; Tan CY; Jiang YY; Go ML; Low BC; Chen YZ
    J Chem Inf Model; 2009 Sep; 49(9):2101-10. PubMed ID: 19689138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lead validation and SAR development via chemical similarity searching; application to compounds targeting the pY+3 site of the SH2 domain of p56lck.
    Macias AT; Mia MY; Xia G; Hayashi J; MacKerell AD
    J Chem Inf Model; 2005; 45(6):1759-66. PubMed ID: 16309282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines.
    Ma XH; Wang R; Tan CY; Jiang YY; Lu T; Rao HB; Li XY; Go ML; Low BC; Chen YZ
    Mol Pharm; 2010 Oct; 7(5):1545-60. PubMed ID: 20712327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validated quantitative structure-activity relationship analysis of a series of 2-aminothiazole based p56(Lck) inhibitors.
    Li J; Du J; Xi L; Liu H; Yao X; Liu M
    Anal Chim Acta; 2009 Jan; 631(1):29-39. PubMed ID: 19046675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M; Vanrens JC; Brugel TA; Maier J; Laufersweiler MJ; Golebiowski A; De B; Easwaran V; Hsieh LC; Rosegen J; Berberich S; Suchanek E; Janusz MJ
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4257-61. PubMed ID: 16757169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.
    Goldberg DR; Butz T; Cardozo MG; Eckner RJ; Hammach A; Huang J; Jakes S; Kapadia S; Kashem M; Lukas S; Morwick TM; Panzenbeck M; Patel U; Pav S; Peet GW; Peterson JD; Prokopowicz AS; Snow RJ; Sellati R; Takahashi H; Tan J; Tschantz MA; Wang XJ; Wang Y; Wolak J; Xiong P; Moss N
    J Med Chem; 2003 Apr; 46(8):1337-49. PubMed ID: 12672234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico prediction and screening of gamma-secretase inhibitors by molecular descriptors and machine learning methods.
    Yang XG; Lv W; Chen YZ; Xue Y
    J Comput Chem; 2010 Apr; 31(6):1249-58. PubMed ID: 19847781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.
    Zhang G; Ren P; Gray NS; Sim T; Liu Y; Wang X; Che J; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Chow D; Martin Seidel H; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5618-21. PubMed ID: 18793846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of virtual screening performance of support vector machines trained by sparsely distributed active compounds.
    Ma XH; Wang R; Yang SY; Li ZR; Xue Y; Wei YC; Low BC; Chen YZ
    J Chem Inf Model; 2008 Jun; 48(6):1227-37. PubMed ID: 18533644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ring-fused pyrazole derivatives as potent inhibitors of lymphocyte-specific kinase (Lck): Structure, synthesis, and SAR.
    Takayama T; Umemiya H; Amada H; Yabuuchi T; Koami T; Shiozawa F; Oka Y; Takaoka A; Yamaguchi A; Endo M; Sato M
    Bioorg Med Chem Lett; 2010 Jan; 20(1):112-6. PubMed ID: 19945867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: Structure, synthesis, and SAR.
    Takayama T; Umemiya H; Amada H; Yabuuchi T; Shiozawa F; Katakai H; Takaoka A; Yamaguchi A; Endo M; Sato M
    Bioorg Med Chem Lett; 2010 Jan; 20(1):108-11. PubMed ID: 19945869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification of cytochrome P450 1A2 inhibitors and noninhibitors by machine learning techniques.
    Vasanthanathan P; Taboureau O; Oostenbrink C; Vermeulen NP; Olsen L; Jørgensen FS
    Drug Metab Dispos; 2009 Mar; 37(3):658-64. PubMed ID: 19056915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
    Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of CYP3A4 inhibition models: comparisons of machine-learning techniques and molecular descriptors.
    Arimoto R; Prasad MA; Gifford EM
    J Biomol Screen; 2005 Apr; 10(3):197-205. PubMed ID: 15809315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based virtual screening approach to identify novel classes of PTP1B inhibitors.
    Park H; Bhattarai BR; Ham SW; Cho H
    Eur J Med Chem; 2009 Aug; 44(8):3280-4. PubMed ID: 19269068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of N-4,6-pyrimidine-N-alkyl-N'-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase.
    Maier JA; Brugel TA; Sabat M; Golebiowski A; Laufersweiler MJ; VanRens JC; Hopkins CR; De B; Hsieh LC; Brown KK; Easwaran V; Janusz MJ
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3646-50. PubMed ID: 16682201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IKKbeta inhibitors identification part I: homology model assisted structure based virtual screening.
    Nagarajan S; Doddareddy Mr; Choo H; Cho YS; Oh KS; Lee BH; Pae AN
    Bioorg Med Chem; 2009 Apr; 17(7):2759-66. PubMed ID: 19285872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.